The drug Remdesivir is showing promise as a treatment for COVID-19 patients. In clinical trials, patients recovered several days sooner than patients who got a placebo, and the U.S. Food and Drug Administration approved its use several weeks ago. Remdesivir’s maker, Gilead, has released 600,000 doses in America. Michigan got almost 11,000 doses, enough to treat 1,200 patients.
To learn more about Remdesivir, WKAR’s Scott Pohl spoke with MSU infectious disease expert Dr. Peter Gulick.